Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

NCT00903006 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Low Accrual

Conditions

Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: MK-0646
DRUG: Dasatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]